Stevanato Group stock
STVNNYSEStevanato Group S.p.A., HealthcareISIN IT0005452658
49Score 49 out of 100, Weak
Price and trend
37 / 100
Price history
−42% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 22% below it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 23).
The price is 42% below its 52-week high. Largest decline in 5 years: 63% (August 2023 to November 2026).
Chart figures for advanced users
- SMA 50$19.37
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$17.93
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)23
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$13.21
- The lowest closing price of the last twelve months.
- Resistance$24.17
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Stevanato Group S.p.A. belongs to the Medical (Instruments & Supplies) industry (Italy) and, with a market value of $3.8B, is number 27 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.27B (up 3.2% year on year) and earnings of $149.42M (up 14%).
- MEQIRI Score 49 out of 100 (Weak): rank 397 of 714 in Healthcare, median 53.
Show more
- The P/E is 24.4 (Medical (Instruments & Supplies) median 34.8, own median of recent years 37.3).
- Our model puts fair value at $12.60, with the price 10% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Modestly valuedP/E 24.4, Medical (Instruments & Supplies) median 34.8, own median 37.3.Valuation 58
Weaknesses
- Negative free cash flowFree cash flow −$86.87K over the last 12 months.Fundamentals 50
- Share price fell sharplyDown 43% over the last 12 months.Momentum 14
- Volatile share priceVolatility 54% a year over the last 12 months.
Its standout strength is stability, while technical analysis and momentum hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price far below its 52-week high
- high price swings
- weak momentum
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $9.00 and expensive above $21.00 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $5.41 (cash-flow model) and $19.80 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 9.3%. At 10.3% the fair value would be $12.12, at 8.3% it would be $13.29.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (34.8).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 6.2% on the twelve months before. Revenue has grown strongly since 2019, at around 13% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 29%, operating 16%, net 12%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 3 Mar 2027in 111 days
- Last reported
- 3 Nov 2026EPS reported 0.18 (expected 0.18)in line with expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 9.8% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- 0.61+0.8%
- Revenue
- $1.42B+0.8%
- Earnings per share
- 0.65−9.8%
- Revenue
- $1.45B−5.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook mixed
Share price after the results: −2.4%Revenue guidance lowered to EUR 1.260 billion to EUR 1.280 billion after a subsidiary sale (about EUR 15 million less), adjusted EBITDA EUR 335 million to EUR 345.2 million and EPS narrowed to EUR 0.60 to EUR 0.62; BDS growth is now seen in the high single digits.
“The divestiture, while small, is expected to be accretive to margins at the central point of our guide, and we now expect adjusted EBITDA between EUR 335 million to EUR 345.2 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $326,750 in total. 8 insiders sold, $561,800 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Morel Donald E JrPurchase
6 Nov 2026, Board
- Shares
- 25,000
- Price
- $13.07
- Value
- $326,750
- Stocchi MauroSale
28 Sept 2026, See Remarks
- Shares
- 13,649
- Price
- $21.50
- Value
- $293,454
- Santel LucianoSale
7 Aug 2026, Board
- Shares
- 2,023
- Price
- $20.09
- Value
- $40,642
Show 6 more
- Dal Lago MarcoSale
7 Aug 2026, Chief Financial Officer
- Shares
- 4,209
- Price
- $20.09
- Value
- $84,559
- Magistretti ElisabettaSale
7 Aug 2026, Board
- Shares
- 2,045
- Price
- $20.09
- Value
- $41,084
- Balachandran MadhavanSale
15 Jun 2026, Board
- Shares
- 1,493
- Price
- $17.09
- Value
- $25,515
- Morel Donald E JrSale
15 Jun 2026, Board
- Shares
- 1,493
- Price
- $17.09
- Value
- $25,515
- Flynn KarenSale
15 Jun 2026, Board
- Shares
- 1,493
- Price
- $17.09
- Value
- $25,515
- Federici William JSale
15 Jun 2026, Board
- Shares
- 1,493
- Price
- $17.09
- Value
- $25,515
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Stevanato Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 49
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- ICU MedicalICUI $4.46B54
- Pulse BiosciencesPLSE $4.19B46
- Envista HoldingsNVST $4.06B72
- Tecan GroupTECN.SW $3.99B53
- SCHOTT Pharma AG & Co. KGaA1SXP.F $3.59B69
- Carl Zeiss MeditecAFX.DE $3.35B64
- AtriCureATRC $2.93B53
- AddLifeALIF-B.ST $2.17B59
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = €0.8987)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 4 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.